ProCE Banner Activity

My Take on the Recent Approval of Selpercatinib for RET Fusion–Positive NSCLC

Clinical Thought
Vamsidhar Velcheti, MD, provides his thoughts on the clinical implications of the recent approval of selpercatinib for RET fusion–positive NSCLC in this commentary.

Released: June 25, 2020

Share

Faculty

Vamsidhar Velcheti

Vamsidhar Velcheti, MD

Professor of Medicine
NYU Grossman School of Medicine
Medical Director
Thoracic Oncology Program
Laura and Isaac Perlmutter Cancer Center
An NCI-designated Comprehensive Cancer Center
New York, New York 

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Faculty Disclosure

Primary Author

Vamsidhar Velcheti, MD

Professor of Medicine
NYU Grossman School of Medicine
Medical Director
Thoracic Oncology Program
Laura and Isaac Perlmutter Cancer Center
An NCI-designated Comprehensive Cancer Center
New York, New York 

Vamsidhar Velcheti, MD, has reported that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, EMD Serono, Foundation Medicine, and Merck.